ONCOLOGY & HEMATOLOGY REVIEW positive monoclonal antibodies led to photothemolysis of CD133-positive glioblastoma cells in vivo and in mice, 14 suggesting that CD133 may represent a useful target to selectively inhibit CSCs in CD133-expressing tumor types.
CD44
CD44, a cell surface adhesion molecule, is the principal receptor for hyaluronate, which is the most abundant extracellular matrix component. 15, 16 CD44 has been suggested to perform functions in CSCs such as mediation of adhesion and homing to the stem cell niche, enhancement of antiapoptotic proteins and surface efflux pump expression, regulation of the cellular redox status and the response to the activation of the canonical Wnt pathway. [17] [18] [19] Future research is needed to elucidate the suitability of CD44
as a CSC marker in GI cancer and its role in tumorigenesis.
EpCAM
Epithelial cell adhesion molecule (EpCAM), initially described in human CRC as a tumor-associated antigen, 20 is expressed highly in a range of human epithelial normal and cancer tissues, including the colon. 21 Several lines of evidence indicate that EpCAM is involved in cell adhesion, proliferation, migration, and cancer and stem cell signaling. 22, 23 Other potential markers
More recently, identified possible markers of CSCs include: CD29/integrin β1, a mucin-like cell adhesion molecule; 24 CD24/HSA, a extracellular matrix protein receptor that is involved in regulation of cell migration, proliferation, survival, differentiation, and death; 25 Lgr5/Gpr49, a receptor for R-spondin proteins; 26 and CD166/ALCAM, a cell adhesion molecule.
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Limitations of cancer stem cell markers
Identification and isolation of CSCs using putative surface markers has received much attention in cancer research. However, heterogeneity among GI tumors and GI tumor subtypes has led to difficulty in pinpointing unique markers. Expression of surface markers varies at different tumor stages and their main regulatory functions are not understood fully. 28 Lack of universal expression of surface markers has obfuscated their use and no optimal combination of markers has been confirmed for the identification of CSCs. Further, non-CSCs have been shown to also express some of these markers. 29 CSC markers are an area of continuous development as more studies identify molecules that may serve as new CSC markers and help to identify CSCs in GI cancers in a tissue-specific manner.
Cancer stemness and epithelial-to-mesenchymal transition
Stemness, initially taken to mean expression of stem cell genes, such as Nanog, Oct4, and Sox2, is a defining property of embryonic and adult stem cells. 30 Stemness can be measured by a cell's ability to form spheres when cultured in stem cell media. 31 Chemotherapy 32 and radiation 33 have been found to induce the expression of stemness genes in cancer cells in vitro, thereby enriching the CSC population in the residual tumor.
Epithelial-to-mesenchymal transition (EMT) is the capacity of epithelial cells to acquire mesenchymal traits to allow local invasion into surrounding tissues and systemic dissemination to distant organ sites. 3 Recent evidence indicates that EMT can induce differentiated cancer cells into a CSC-like state, suggesting a functional link between stemness and EMT.
34
Stemness pathways associated with cancer stem cells in gastrointestinal malignanciestherapeutic targets
The desired aim is to overcome resistance to chemotherapeutics and reduce therapy-related toxicity by developing treatments that are specific for CSCs and that are not toxic to healthy tissues. Examples of stemness pathways as therapeutic targets are discussed below.
Nanog
Nanog, an essential regulator of embryonic stem cell self-renewal that inhibits differentiation, is overexpressed in a variety of cancers including those of the GI system 35, 36 High levels of Nanog expression are associated with advanced stages of cancer and a poor prognosis, suggesting that it may play a key role in tumor transformation, tumorigenesis, and tumor metastasis. 35 Nanog is involved in a complex regulatory network that determines cell fate, proliferation, and apoptosis ( Table 2) . It is therefore a promising therapeutic target. Genetic ablation of Nanog in SW620 colorectal carcinoma cells suppressed both tumor growth in athymic nude mice and cell proliferation in vitro. 37 Further, ablation mediated by short hairpin RNA decreased the expression of core CSC transcription factors, supporting a role for Nanog as a signali ng hub in CSCs.
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BBI503 is an orally administered investigational agent designed to inhibit Nanog and other CSC pathways by targeting kinases. Early signs of antitumor activity have been observed in pre-treated patients with advanced cancer (BBI503-101, NCT01781455). 39 In this ongoing, first-in-human, open-label phase I dose-escalation study, 11 of 20 evaluable patients (55%) had stable disease with a median time to progression of 16 weeks.
Of these 11 patients, tumor regression and/or prolonged stable disease (≥16 weeks) were observed in 10 patients (50% all enrolled patients).
Further, in biopsied tumor tissues, dose-dependent pharmacodynamics effects of decreased expression level of Nanog were observed. The recommended phase II dose of continuous once daily BBI503 was 300 mg/day. At this dose, BBI503 was shown to be well tolerated and the pharmacokinetic profile supports once-daily dosing as an acceptable administration schedule. Mild GI adverse events were observed, including grade 1 and 2 diarrhea, adnominal cramps, nausea, and anorexia. Grade 3 diarrhea was noted in two patients at 450 mg once daily.
In an extension study of BBI503-101, BBI503 was administered to patients with advanced CRC. 40 Patients (n=47) with heavily pre-treated CRC were enrolled. The disease control rate in evaluable patients (n=39) with high Nanog expression (biomarker positive) was 56%, whereas in biomarkernegative patients, the disease control rate was 13% (p=0.04). Median overall survival in biomarker-positive patients (intent-to-treat) was 38 weeks compared with 16 weeks in biomarker-negative patients (p=0.089
Log-Rank). BBI503 was well tolerated at the recommended phase II dose of 300 mg once daily; grade 3 adverse events were diarrhea (n=5), fatigue (n=4), nausea (n=1), and weight loss (n=1).
STAT3
STAT3 is a latent cytoplasmic transcription factor that appears to be activated constitutively in many cancers, to play a pivotal role in metastasis and tumor growth, and is associated with decreased survival. [41] [42] [43] It was first discovered in 1994 as a signal transducer from cell surface receptors to the nucleus. 44 STAT activation has been suggested to be important at every stage of metastasis ( Figure 2 ).
Napabucasin (BBI608) is an orally administered investigational agent that
has been designed to inhibit CSC pathways including STAT3, Nanog, and β-catenin pathways by targeting STAT3. 41, 45 Pre-clinical data indicate that BBI608 inhibits STAT3-driven transcription and suppresses metastasis Reproduced from Kamran et al. 41 Grothey FINAL. A phase I trial (n=55) of OMP-21M18, which targets Notch ligand Delta like 4, revealed anti-tumor activity and good tolerability at doses of ≤5 mg weekly.
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Wnt/β-catenin Notch signaling can also interact with Wnt/β-catenin signaling ( Figure   4) . 55, 61 The Wnt pathway has a key role in embryogenesis, with effects that 77 Transforming growth factor-β signaling is important for self-renewal and maintenance in the formation of GI cancers. 78, 79 Hedgehog describes a complex of molecules that regulate cell differentiation, regeneration, and stem cell properties. 80 It is central to the development and homeostasis of gut tissue and is deregulated in GI cancers. 81 The stemness factor Nanog is one of the major targets for Hedgehog signaling. 82 Specific inhibitors of Hedgehog signaling, such as vismodegib (GDC-0449), and sonidegib (LDE225) are being examined in clinical trials in addition to the approved indication for basal cell carcinoma. 83 Addition of vismodegib to oxaliplatin with 5-FU and folinic acid (FOLFOX) chemotherapy did not improve progression-free survival in patients with gastric and gastroesophageal junction cancer. 84 Phosphatase and tensin homolog (PTEN) is a phosphatase that antagonizes the activity of PI3 kinase; PTEN-deficient mice demonstrate an increase in intestinal stem cells, which results in excess crypt formation. 85 The PTEN pathway helps regulate the proliferative rate and number of intestinal stem cells.
Induction of cellular quiescence
An alternative to the CSC inhibition discussed involves the chemical induction of cellular quiescence. This is a state of reversible cell cycle arrest, associated with reduced translation rate, activation of autophagy, and a low metabolic rate as characterized by decreased glycolysis. 86 This is a burgeoning area of research and it has been suggested that the efficacy of CSC inhibitors and conventional therapies may be enhanced if used in combination with chemoquiescence-inducing agents such as chloroquine and its analogues.
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Cancer stem cell inhibitor trial design
Given that the CSCs constitute only a small proportion of an established tumor, a response rate read-out might not be the most suitable endpoint for a CSC inhibitor trial. The effect could be delayed and may better be captured with time-related endpoints using response criteria developed for immunotherapies.
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Conclusion
The discovery of CSCs-which have been described in GI neoplasms such as colon, pancreas, liver, and gastroesophageal tumors-provides promise of a suitable target for improving future oncological treatment. CSCs of the GI system are well suited to research as they are abundant, and have proliferative potential, as well as a uniform structural arrangement which is maintained under tightly controlled signaling pathways. The CSC model has been criticized for failing to take into account the heterogeneous nature of GI cancers. However, CSCs themselves may evolve over time, giving rise to cells that are both genetically and functionally heterogeneous. 29 Accurate targeting of CSCs must be preceded by precise identification and characterization of those cells. More research is therefore needed to determine which and how many markers need to be considered in the identification of GI CSCs.
CSC-targeted therapies may represent a new treatment modality in patients with cancer. Research continues to target CSCs to render them more chemo-and radio-sensitive, inhibit their potential to proliferate and undergo EMT, thus decreasing the incidence of metastases.
Future challenges include optimizing the study design for determining investigational agents' efficacy in cancer. ■
